[Diagnostic criteria for mild cognitive impairment in a cohort of 100 subjects].

Rev Neurol (Paris)

Unité de neuropsychologie-CM2R, CHU de Saint-Etienne, CHU Bellevue, 42055 Saint-Etienne cedex 02, France.

Published: December 2009

Introduction: Tracking can be proposed for subjects with prodromal sates of Alzheimer disease (AD) or people with mild cognitive impairment (MCI) at risk to develop dementia who present a memory complaint.

Patients And Methods: We present a cohort of 100 subjects who attended a French memory unit with a diagnostic of MCI. We applied the different definitions used in daily practice. We used the following diagnostic criteria: amnestic MCI (MCIa), multiple domain impairment (MDI), single non-memory dysfunction impairment (SDI), and prodromal Alzheimer's disease (Prod-AD), using only the neuropsychological episodic memory criteria. We also analyzed the population of subjects presenting MCI and vascular risk factors.

Results: Ninety-nine subjects met the criteria of MCIa, 43 met the criteria of isolated MCIa; 56 met the criteria of MDI; one met the criteria of SDI; 40 met the criteria of MAPD; 58 met the criteria of MCI with vascular risk factors.

Discussion: Using the diagnostic criteria of MCI can lead to clinical ambiguity because the population recruited on the bases of memory complaint is highly variable. Moreover, many subjects meet many definitions. This overlap of the classifications further complicates the decision to favor one criterion over another. In clinical practice, a classification system using the concepts of MCI, MDI and SDI seems to be quite operational but cut-offs are necessary for the tests applied, in addition to a clarified choice of which tests to use.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2009.03.011DOI Listing

Publication Analysis

Top Keywords

met criteria
24
criteria
9
mild cognitive
8
cognitive impairment
8
cohort 100
8
diagnostic criteria
8
mci vascular
8
vascular risk
8
mcia met
8
criteria mci
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

STEM Neurology & Neuropsychological0 Research Group Egypt (SNRGE), Port Said, Port Said, Egypt.

Background: Donepezil, an acetylcholinesterase inhibitor (AChEI), is an FDA-approved drug to treat these neurodegenerative diseases, e.g., Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI).

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AbbVie Inc., North Chicago, IL, USA.

Background: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.

View Article and Find Full Text PDF

Background: HIV-associated neurocognitive disorders (HAND) are prevalent complications of ageing with treated HIV, disproportionally affecting sub-Saharan Africa. Causal HAND treatments are lacking worldwide; therefore, reversible factors are important to explore. Sleep duration and quality are frequently associated with risk of cognitive impairments.

View Article and Find Full Text PDF

Dementia Care Research and Psychosocial Factors.

Alzheimers Dement

December 2024

Weill Cornell Medicine, New York City, NY, USA.

Background: Early detection of Alzheimer's disease (AD) can improve prognosis, given new anti-amyloid therapies. Both positron emission tomography (PET) and magnetic resonance (MR) imaging biomarkers are currently used (1). 48F-Fluorodeoxyglucose-PET (FDG-PET) can detect neurodegeneration-related hypometabolism but is costly and not easily accessible (2).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!